Ultime notizie per Becton Dickinson (NYSE:BDX) Azioni

Becton Dickinson

Becton, Dickinson

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.

Becton, Dickinson and Company Common Stock

Becton Dickinson & Co

News

BD Launched The New BD Intraosseous Vascular Access System, Enabling Access For Rapid Delivery Of Fluids Or Medication In Critical Emergency Situations

Looking into the current session, Becton Dickinson Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) shares are trading at $240.91, after a 0.50% spike. Moreover, over the past month, the stock went up by 1.87%, but in the past year, fell by 5.73%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1729693827_0.png" alt="Past Year Chart" />

<h3>Evaluating Becton Dickinson P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Becton Dickinson has a lower P/E than the aggregate P/E of 261.98 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1729693827_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Becton Dickinson

WIIM

Shares of surgical tool and medical instrument stocks are trading higher in sympathy with Intuitive Surgical, which gained on strong Q3 earnings.

The automated solution from the BD and Hamilton collaboration standardizes traditionally manual processes and speeds the generation of material for genetic sequencing.
The solution includes the newly released BD&reg;&nbsp;OMICS-One XT WTA Assay and the Hamilton&nbsp;Microlab&nbsp;NGS STAR automated liquid handling platform. Because the NGS STAR is already installed in many laboratories and facilities worldwide, more researchers, processing samples across an array of genomics applications, can easily integrate the new automation-ready BD&reg;&nbsp;assay into existing workflows.

BD Reveals Commercial Launch Of New Robotics Solution That Will Enable Automation

Terms of the settlement agreement include cases in both the&nbsp;Rhode Island&nbsp;consolidated litigation and the federal multidistrict litigation in&nbsp;Ohio.&nbsp;
The aggregate amount payable pursuant to this settlement is within the company&#39;s current product litigation reserve for this matter and will be paid out over a multi-year period.
As a result, the settlement amount is already recorded as a liability within BD&#39;s consolidated balance sheet and the agreement will not result in an incremental charge to the company&#39;s consolidated income statement. BD believes this agreement is in the best interest of all parties and is structured to eliminate uncertainty for all stakeholders related to the settled cases. &nbsp;The hernia mass tort litigation represents a large majority of BD&#39;s total product litigation reserve.

Legal

BD Reaches Agreement To Resolve Vast Majority Of Its Existing Hernia Litigation, Terms Confidential; Expects Settlement Not To Change Cash Flow Goals Or Capital Allocation Strategy

Evercore ISI Group analyst Vijay Kumar maintains Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) with a Outperform and raises the price target from $286 to $290.

Price Target

Analyst Ratings

Evercore ISI Group Maintains Outperform on Becton Dickinson, Raises Price Target to $290

4 analysts have expressed a variety of opinions on Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Becton Dickinson, presenting an average target of $270.0, a high estimate of $280.00, and a low estimate of $255.00. Surpassing the previous average price target of $265.00, the current average has increased by 1.89%.
<img src="https://www.benzinga.com/files/images/story/2024/1727794902_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Becton Dickinson by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$270.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$255.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Becton Dickinson. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Becton Dickinson compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Becton Dickinson's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BDX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Becton Dickinson analyst ratings.</a>
<h2>Get to Know Becton Dickinson Better</h2>
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
<h3>Becton Dickinson: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Becton Dickinson's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 2.3%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Becton Dickinson's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.76%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Becton Dickinson's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.89%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Becton Dickinson's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.89%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Becton Dickinson's debt-to-equity ratio stands notably higher than the industry average, reaching 0.75. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Becton Dickinson Through 4 Analysts

Citigroup analyst Joanna Wiensch upgrades Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) from Neutral to Buy and raises the price target from $255 to $275.

Upgrades

Citigroup Upgrades Becton Dickinson to Buy, Raises Price Target to $275

<ul>
<li>After implementing BD HealthSight Diversion Management software, the Ochsner facility observed a 55% increase in the number of charting discrepancies. This increase is attributed to the software's ability to track a broader range of discrepancies than was previously possible with existing procedures at the study site, such as whole dose waste, cancelled transactions and drugs dispensed after patient discharge.</li>
<li>The study also highlighted efficiency improvements in the facility's efforts to reconcile incidents of potential drug diversion in the operating room. Despite the increase in the volume of charting discrepancies, the percentage of incidents that were able to be resolved by the operating room analyst increased by 14% after software implementation and the number of cases requiring additional documentation by providers decreased by 10%. When a full investigation was required, the software reduced the time required for an auditor to review referred cases of potential diversion from an average of three business days to 50 minutes.</li>
<li>The study measured the facility's ability to identify, reconcile and investigate potential incidents of drug diversion across their 34 operating rooms where more than 55,000 surgeries are performed and more than 100,000 doses of controlled substances are dispensed annually.</li>
</ul>

Health Care

General

Becton, Dickinson Announced New Data That Highlights How Its Advanced Artificial Intelligence Technology Can Help Health Systems Better Identify Incidents Of Controlled Substance Diversion In The Operating Room

Biotech

QGEN

QIAGEN And BD Joint Venture, PreAnalytiX, Launches Solution For Liquid Biopsy From Urine Samples

Becton, Dickinson And Company Disclosed The Commercial Release Of The BD Neopak Xtraflow Glass Prefillable Syringe And The Latest Capacity Expansion Of The BD Neopak Glass Prefillable Syringe Platform

Becton Dickinson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) short percent of float has fallen 9.33% since its last report. The company recently reported that it has 1.98 million shares sold short, which is 0.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.34 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Becton Dickinson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724429720_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Becton Dickinson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Becton Dickinson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Becton Dickinson's peer group average for short interest as a percentage of float is 4.62%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(BDX) - Analyzing Becton Dickinson's Short Interest

Becton Dickinson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) short percent of float has fallen 6.25% since its last report. The company recently reported that it has 2.16 million shares sold short, which is 0.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Becton Dickinson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723044621_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Becton Dickinson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Becton Dickinson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Becton Dickinson's peer group average for short interest as a percentage of float is 4.63%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Becton Dickinson's Recent Short Interest

Raymond James analyst Jayson Bedford maintains Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) with a Outperform and lowers the price target from $275 to $270.

Raymond James Maintains Outperform on Becton Dickinson, Lowers Price Target to $270

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$55.00</td>
<td>$27.0K</td>
<td>19.1K</td>
<td>6.2K</td>
</tr>
<tr>
<td>DGX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$145.00</td>
<td>$35.2K</td>
<td>1.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>BDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$230.00</td>
<td>$31.3K</td>
<td>2.1K</td>
<td>586</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/30/24</td>
<td>$185.00</td>
<td>$42.5K</td>
<td>237</td>
<td>402</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/02/24</td>
<td>$57.00</td>
<td>$31.2K</td>
<td>333</td>
<td>318</td>
</tr>
<tr>
<td>FULC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$8.00</td>
<td>$44.0K</td>
<td>5.6K</td>
<td>100</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$860.00</td>
<td>$157.0K</td>
<td>381</td>
<td>30</td>
</tr>
<tr>
<td>TMDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$110.00</td>
<td>$27.2K</td>
<td>12</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 169 day(s) on January 17, 2025. Parties traded 196 contract(s) at a $55.00 strike. This particular call needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $27.0K, with a price of $138.0 per contract. There were 19145 open contracts at this strike prior to today, and today 6217 contract(s) were bought and sold. 
• Regarding DGX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>), we observe a put option sweep with bearish sentiment. It expires in 15 day(s) on August 16, 2024. Parties traded 279 contract(s) at a $145.00 strike. This particular put needed to be split into 48 different trades to become filled. The total cost received by the writing party (or parties) was $35.2K, with a price of $130.0 per contract. There were 1016 open contracts at this strike prior to today, and today 1033 contract(s) were bought and sold. 
• For BDX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), we notice a put option sweep that happens to be bearish, expiring in 15 day(s) on August 16, 2024. This event was a transfer of 101 contract(s) at a $230.00 strike. This particular put needed to be split into 33 different trades to become filled. The total cost received by the writing party (or parties) was $31.3K, with a price of $310.0 per contract. There were 2138 open contracts at this strike prior to today, and today 586 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option trade with bullish sentiment. It expires in 29 day(s) on August 30, 2024. Parties traded 50 contract(s) at a $185.00 strike. The total cost received by the writing party (or parties) was $42.5K, with a price of $850.0 per contract. There were 237 open contracts at this strike prior to today, and today 402 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be bullish, expiring in 1 day(s) on August 2, 2024. This event was a transfer of 130 contract(s) at a $57.00 strike. The total cost received by the writing party (or parties) was $31.2K, with a price of $240.0 per contract. There were 333 open contracts at this strike prior to today, and today 318 contract(s) were bought and sold. 
• Regarding FULC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>), we observe a call option sweep with bearish sentiment. It expires in 169 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $8.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $44.0K, with a price of $440.0 per contract. There were 5621 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option sweep that happens to be bearish, expiring in 169 day(s) on January 17, 2025. This event was a transfer of 20 contract(s) at a $860.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $157.0K, with a price of $7850.0 per contract. There were 381 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
• For TMDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), we notice a call option trade that happens to be neutral, expiring in 169 day(s) on January 17, 2025. This event was a transfer of 5 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $27.2K, with a price of $5450.0 per contract. There were 12 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

FULC

TMDX

VKTX

8 Health Care Stocks With Whale Alerts In Today's Session

Becton, Dickson and Co. shares are trading lower after the company reported mixed Q3 financial results.

Guidance

BD Sees FY24 Adj. EPS $13.05-$13.15 vs $13.04 Est., Adj. Revenues $20.1B-$20.2B

Becton, Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) reported quarterly earnings of $3.50 per share which beat the analyst consensus estimate of $3.31 by 5.74 percent. The company reported quarterly sales of $4.990 billion which missed the analyst consensus estimate of $5.076 billion by 1.70 percent. This is a 2.30 percent increase over sales of $4.878 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Becton, Dickinson Q3 2024 Adj. EPS $3.50 Beats $3.31 Estimate, Sales $4.990B Miss $5.076B Estimate

Throughout the last three months, 5 analysts have evaluated Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $281.2, a high estimate of $312.00, and a low estimate of $255.00. This current average has decreased by 0.02% from the previous average price target of $281.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1722009670_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Becton Dickinson. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$255.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$274.00</td>
<td>-</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$312.00</td>
<td>$305.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Becton Dickinson. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Becton Dickinson compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Becton Dickinson's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Becton Dickinson's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BDX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Becton Dickinson analyst ratings.</a>
<h2>Discovering Becton Dickinson: A Closer Look</h2>
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures pre-filled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2023 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
<h3>Financial Milestones: Becton Dickinson's Journey</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Becton Dickinson showcased positive performance, achieving a revenue growth rate of 4.65% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Becton Dickinson's net margin is impressive, surpassing industry averages. With a net margin of 10.64%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Becton Dickinson's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.11%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Becton Dickinson's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.01%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Becton Dickinson's debt-to-equity ratio is below the industry average at 0.7, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Becton Dickinson Analyst Ratings

Stifel analyst Rick Wise maintains Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) with a Buy and raises the price target from $270 to $280.

Stifel Maintains Buy on Becton Dickinson, Raises Price Target to $280

The medical devices industry is on the verge of an incoming boom, fueled by its growing demand and technological advancements. In this evolving landscape, investors could scoop up shares of robust medical device stocks Alcon (ALC), Becton, Dickinson (BDX), and Abbott (ABT) for solid gains. Read more… As innovation continues to shape nearly every industry, the medical sector is no exception. Thanks to cutting-edge technology and AI integration, the industry is experiencing significant growth, driven by increasing demand for advanced healthcare solutions, particularly in diagnostics and surgeries.
Given this backdrop, investors looking for growth opportunities could invest in fundamentally sound medical device stocks Alcon Inc. (<a href="https://stocknews.com/stock/ALC/">ALC</a>), Becton, Dickinson and Company (<a href="https://stocknews.com/stock/BDX/">BDX</a>), and Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>).
The medical devices industry is on the cusp of significant growth, driven by advancements in technology, increasing healthcare needs, and rising aging populations. Emerging trends like artificial intelligence, robotics, and telemedicine are reshaping how healthcare is delivered, offering more efficient, personalized, and accessible solutions for patients worldwide.
That said, AI has been a game-changer in the industry, driving breakthroughs in predictive diagnostics, remote monitoring, and precision medicine. Innovations like AI-powered diagnostic tools, wearable health devices, and robotic surgery systems are revolutionizing patient care.
The FDA has already authorized <a href="https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices#:~:text=the%20FDA%20has%20authorized%20950%20AI/ML%2Denabled%20medical%20devices.">950 AI/ML-enabled medical devices</a>, enhancing the industry's potential. These technologies promise faster diagnoses, more precise treatments, and significantly improved patient outcomes, positioning AI as a cornerstone in the future of healthcare innovation.
According to a study by KPMG, global annual medical device sales are forecasted to <a href="https://kpmg.com/us/en/articles/2023/medical-devices-2030.html#:~:text=The%20medical%20device%20industry%20is,US%24800%20billion%20by%202030%20.">hit $800 billion by 2030</a>. Moreover, as per a study by Mordor Intelligence, the medical devices industry is poised for steady growth as its market size is anticipated to reach $893.07 billion by 2029, exhibiting a <a href="https://www.mordorintelligence.com/industry-reports/global-medical-device-technologies-market-industry?network=g&amp;source_campaign=&amp;utm_source=google&amp;utm_medium=cpc&amp;matchtype=b&amp;device=c&amp;gad_source=1&amp;gclid=Cj0KCQjwpP63BhDYARIsAOQkATb9SdZ7QZMMYB0trPXq_zr3V73FHtcX5g9Z7xWnrv4R67MwdKzHOV0aApKdEALw_wcB">CAGR of 7%</a>.
Considering these optimistic trends, let's take a look at three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry stocks in detail, beginning with #3.
Stock #3: Alcon Inc. (<a href="https://stocknews.com/stock/ALC/">ALC</a>)
Headquartered in Geneva, Switzerland, is an eye care company that offers a range of products through two key segments: Surgical and Vision Care. The Surgical business focuses on ophthalmic products for cataract surgery, while the Vision Care business offers contact lenses and ocular health products.
On September 6, ALC <a href="https://investor.alcon.com/news-and-events/press-releases/news-details/2024/Alcon-Debuts-Latest-Digital-Innovations-SMARTCataract-DX-and-NGENUITY-1.5-at-ESCRS-2024-y6dT6v9S06/default.aspx">unveiled its latest innovations</a> at the European Society of Cataract and Refractive Surgeons (ESCRS) annual meeting. The SMARTCataract DX digital planning solution, powered by the ARGOS&#xAE; Biometer, enhances workflow efficiency for practices, positioning ALC as a key player in the eye care sector.
Additionally, ALC introduced the NGENUITY&#xAE; 1.5 with connectivity capabilities, enabling image-guided 3D cataract surgery with the ARGOS Biometer. This provides superior visualization, driving better outcomes. With the rising global demand for cataract surgeries, ALC's innovations would help meet growing needs while strengthening its industry leadership.
On July 1, ALC <a href="https://investor.alcon.com/news-and-events/press-releases/news-details/2024/Alcon-Completes-Acquisition-of-BELKIN-Vision-Expanding-Glaucoma-Portfolio-with-Direct-Selective-Laser-Trabeculoplasty-DSLT-Device---2024-F7U9xE-k6o/default.aspx">completed its acquisition</a> of BELKIN Vision for $81 million, including $65 million in cash. The acquisition expands ALC's glaucoma portfolio with BELKIN Vision's Direct Selective Laser Trabeculoplasty (DSLT) technology, securing robust growth opportunities and future advancements in eye care.
ALC's net sales and other revenues for the fiscal second quarter that ended June 30, 2024, increased 3.1% year-over-year to $2.50 billion. Its gross profit marginally grew from the year-ago value to $1.54 billion. The company's core net income totaled to $367 million and $0.74 per share, up 7.6% and 7.2% from the prior year's quarter, respectively.
Analysts expect ALC's revenue and EPS for the fiscal third quarter (which ended September 2024) to increase 6% and 12.7% year-over-year to $2.47 billion and $0.74, respectively. Also, the company surpassed the consensus EPS estimate in three of four trailing quarters.
Shares of ALC have surged 19.7% over the past six months and 26.3% over the past year to close the last trading session at $94.52.
ALC's bright prospects are mirrored in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
ALC has an A grade for Stability and a B for Growth. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, the stock is ranked #36 out of 135 stocks.
<a href="https://stocknews.com/stock/ALC/">Click here</a> to access additional ALC ratings for Momentum, Sentiment, Value, and Quality.
Stock #2: Becton, Dickinson and Company (<a href="https://stocknews.com/stock/BDX/">BDX</a>)
BDX designs, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. It serves healthcare institutions, physicians, life science researchers, clinical laboratories, and the general public. The business operates through three segments: BD Medical; BD Life Sciences; and BD Interventional.
On October 14, BDX <a href="https://investors.bd.com/news-events/press-releases/detail/854/bd-announces-new-robotics-solution-to-automate-standardize-single-cell-research">announced the commercial launch</a> of the first in a family of high-throughput, robotics-compatible reagent kits that enable automation to ensure greater consistency and increased efficiency of large-scale, single-cell discovery studies.
With advancements in robotics solutions, BDX could accelerate the pace of discovery in oncology and immunology and gather a significant market presence in the medical devices industry.
On September 18, BDX <a href="https://investors.bd.com/news-events/press-releases/detail/850/bd-expands-capacity-for-advanced-prefillable-syringes-and-enhances-injection-experience-for-the-next-generation-of-biologics">announced the commercial release</a> of the BDX Neopak XtraFlow Glass Prefillable Syringe and expanded production capacity for its BDX Neopak Glass Prefillable Syringe platform.
By scaling production, BDX is expected to strengthen its position in the prefillable syringe market, supporting the pharmaceutical industry's need for high-quality, efficient drug delivery systems.
During the fiscal third quarter that ended on June 30, 2024, BDX's adjusted revenues increased 3.7% year-over-year to $5.06 billion. Its <a href="https://www.investopedia.com/terms/o/operatingincome.asp">operating income</a> grew 9.7% from the prior year to $602 million.
Moreover, the company's net income was $487 million, reflecting a 19.7% year-over-year growth. Meanwhile, its adjusted EPS rose 18.2% from the previous year's quarter to $3.50.
Street expects BDX's revenue and EPS for the fiscal fourth quarter that ended September 2024 to increase 5.2% and 10.1% year-over-year to $5.35 billion and $3.77, respectively. In addition, the company surpassed the consensus EPS estimates in three of the trailing four quarters.
Over the past month, the stock has gained 3.9% to close the last trading session at $240.33.
BDX's POWR Ratings reflect its robust prospects. It has an overall rating of B, translating to a Buy in our proprietary system.
BDX has a B grade for Growth, Stability, and Sentiment. It is ranked #31 in the 135-stock Medical – Devices &amp; Equipment industry.
<a href="https://stocknews.com/stock/BDX/">Click here</a> to see BDX's ratings for Value, Momentum, and Quality.
Stock #1: Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>)
ABT discovers, develops, manufactures, and sells a diverse range of healthcare products. The company operates in four segments: Established Pharmaceutical Products; Diagnostic Products; Nutritional Products; and Medical Devices, delivering comprehensive solutions to address various healthcare needs globally.
On October 10, ABT <a href="https://abbott.mediaroom.com/2024-10-10-Abbott-Advances-Pulsed-Field-Ablation-Clinical-Studies-and-Launches-New-Technology-to-Support-Advanced-Cardiac-Mapping">announced significant milestones</a> to expand its pulsed field ablation (PFA) solutions in electrophysiology. The company completed early enrollment for the VOLT-AF IDE Study, supporting its Volt&#x2122; PFA System, and launched the FOCALFLEX trial to evaluate the TactiFlex&#x2122; Duo Ablation Catheter, Sensor Enabled&#x2122; (SE), for treating patients with paroxysmal atrial fibrillation.
Additionally, ABT received FDA clearance for its Advisor&#x2122; HD Grid X Mapping Catheter, Sensor Enabled&#x2122;, designed to enhance cardiac mapping for both PFA and radiofrequency (RF) ablation cases. The cutting-edge technology ensures precise visualization of cardiac anatomy, driving better outcomes in ablation procedures.
On September 5, ABT <a href="https://abbott.mediaroom.com/2024-09-05-Abbotts-Lingo-TM-Continuous-Glucose-Monitor-for-Health-and-Wellness-Now-Available-in-the-U-S">announced the U.S. launch</a> of its Lingo Continuous Glucose Monitor, a non-prescription system designed for individuals aiming to enhance their health and wellness through real-time glucose tracking and personalized insights.
With new innovations and FDA clearances, ABT is continuously trying to re-establish itself as a market leader in the pharma landscape and ensuring stable growth prospects for the company in the future.
ABT's net sales for the fiscal third quarter, which ended September 30, 2024, increased 4.9% year-over-year to $10.64 billion. Its operating earnings grew 12.8% from the year-ago value to $1.86 billion. Moreover, adjusted net earnings came in at $2.12 billion or $1.21 per share, up 6% and 6.1% from the prior year's period, respectively.
The consensus revenue estimate of $11.03 billion for the fiscal fourth quarter ending December 2024 reflects a rise of 7.8% year-over-year. Its EPS for the same period is expected to increase 12.8% from the prior year's period to $1.34. Moreover, ABT topped the consensus revenue and EPS estimates in all four trailing quarters.
Shares of ABT have surged 11.3% over the past six months and 28% over the past year to close the last trading session at $117.89.
ABT's robust fundamentals are reflected in its POWR Ratings. It has an overall rating of B, which translates to a Buy in our proprietary rating system.
ABT has a B grade for Stability and Sentiment. Within the same industry, it is ranked #19. To see ABT's Growth, Value, Momentum, and Quality ratings, <a href="https://stocknews.com/stock/ABT/">click here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>
&nbsp;
&nbsp;

<hr />
ABT shares were unchanged in premarket trading Friday. Year-to-date, ABT has gained 9.24%, versus a 23.68% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/abt-bdx-alc-3-medical-device-stocks-to-buy-for-consistent-growth/>3 Medical Device Stocks to Buy for Consistent Growth</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Medical Device Stocks to Buy for Consistent Growth

Becton, Dickinson and Company announced a strategic collaboration with Ypsomed, a developer of injection systems, to advance self-injection solutio...

Becton Dickinson announces strategic collaboration with Ypsomed

Wall Street Week Ahead

Becton, Dickinson And HP Among 13 Companies To Announce Annual Dividend Increases In First Half Of November

Notable companies reporting before tomorrow's open, with earnings consensus, include Transdigm (TDG), consensus $9.32… Becton Dickinson (BDX), cons...

Notable companies reporting before tomorrow's open

Becton, Dickinson Q4 2024 Earnings Preview

ABNB

ANET

CTVA

DDOG

ELAN

EVRG

FANG

FLIC

FTNT

GDRX

GILD

ILMN

KVUE

LANC

LECO

MCHP

MELI

MRNA

MSEX

PARA

PARAA

PENN

PLNT

PLTK

PLTR

PZZA

QCOM

RACE

SBUX

TTWO

USFD

VRTX

YETI

Press Releases

BD Completes Acquisition of Critical Care from Edwards Lifesciences

BD Expands Capacity for Advanced Prefillable Syringes and Enhances Injection Experience for the Next Generation of Biologics

PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples

New Data Reveals BD's Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion

BD Reaches Agreement to Resolve Vast Majority of Hernia Litigation

BD to Announce its Fiscal 2024 Fourth Quarter and Full Year Financial Results

BD Announces New Robotics Solution to Automate, Standardize Single-Cell Research

BD Named Among the 100 Best Corporate Citizens of 2024

Women in Canada Can Now Collect Their Own Sample at Home for Cervical Cancer Screening

BD Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations

Comments

Becton Dickinson

Notizie

Ultime notizie per Becton Dickinson (NYSE:BDX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO